Department of Otolaryngology - Head and Neck Surgery, Boston Medical Center, Boston, Massachusetts.
Department of Radiation Oncology, Boston Medical Center, Boston, Massachusetts.
Head Neck. 2018 Jun;40(6):1174-1184. doi: 10.1002/hed.25087. Epub 2018 Feb 8.
The purpose of this study was to evaluate the role of postoperative adjuvant radiotherapy (surgery + adjuvant RT) versus adjuvant chemoradiotherapy (surgery + adjuvant CRT) in patients with T4N0M0, stage IV head and neck squamous cell carcinoma (HNSCC).
Between 1998 and 2011, 3518 and 885 patients were treated with surgery + adjuvant RT and surgery + adjuvant CRT, respectively. Three-year overall survival (OS) rates were determined and crude and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were computed.
Median follow-up was 41.8 months with 2193 reported deaths. The 3-year OS was 67.5% for surgery + adjuvant RT and 70.5% for surgery + adjuvant CRT (P = .013). For negative margins, the corresponding 3-year OS was 70.1% and 74.9% (P = .005). For positive margins, the corresponding 3-year OS was 56.0% and 60.6% (P = .079). On multivariate analysis, the beneficial effect for adjuvant CRT over adjuvant RT was not significant (HR 0.90; CI 0.79-1.03; P = .124).
In this cohort of patients with T4N0 HNSCC treated with surgery, there was no observed survival benefit of adjuvant CRT over adjuvant RT on multivariate analysis.
本研究旨在评估术后辅助放疗(手术+辅助 RT)与辅助放化疗(手术+辅助 CRT)在 T4N0M0、IV 期头颈部鳞状细胞癌(HNSCC)患者中的作用。
1998 年至 2011 年间,分别有 3518 例和 885 例患者接受手术+辅助 RT 和手术+辅助 CRT 治疗。确定了 3 年总生存率(OS),计算了粗死亡率和调整后的危险比(HR)及其 95%置信区间(CI)。
中位随访时间为 41.8 个月,报告死亡 2193 例。手术+辅助 RT 的 3 年 OS 为 67.5%,手术+辅助 CRT 为 70.5%(P=0.013)。对于阴性切缘,相应的 3 年 OS 为 70.1%和 74.9%(P=0.005)。对于阳性切缘,相应的 3 年 OS 为 56.0%和 60.6%(P=0.079)。多变量分析显示,辅助 CRT 相对于辅助 RT 的有益效果不显著(HR 0.90;CI 0.79-1.03;P=0.124)。
在本队列中,对于接受手术治疗的 T4N0 HNSCC 患者,多变量分析未观察到辅助 CRT 比辅助 RT 有生存获益。